CLINICAL TRIALS PROFILE FOR SIMVASTATIN

505(b)(2) Clinical Trials for simvastatin

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT01953835 ↗	A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184	Completed	GlaxoSmithKline	Phase 1	2013-10-04	This study is a Phase I, two-part, open-label study designed to evaluate the effect of repeated doses of GSK2586184 on the pharmacokinetics (PK) of Simvastatin and Rosuvastatin in healthy volunteers (Cohort A), and to evaluate the pharmacokinetics of a new tablet formulation of GSK2586184 in healthy male volunteers (Cohort B). Cohort A is a single sequence drug interaction study in which 28 subjects (14 female and 14 male subjects) will be enrolled. Each subject will receive single doses of Simvastatin and Rosuvastatin on two occasions, once alone and once following administration of repeated doses of GSK2586184. Cohort B is a 3-way crossover PK study in which 9 male subjects will be randomized (3 subjects to each treatment sequence). Each subject will receive a single dose of the standard formulation of GSK2586184 with food and two doses of a new formulation of GSK2586184, once with food and once in a fasted state, according to their treatment sequence, with a 3-day wash out between doses. The primary aim of the study is to investigate the effects of GSK2586184 on the pharmacokinetics of the 2 statins and to assess the impact of dosing with and without food on a new formulation of GSK2586184 tablet.
OTC	NCT04973800 ↗	Simvastatin and Emotional Processing (OxSTEP)	Recruiting	Wellcome Trust	N/A	2021-06-21	Simvastatin is being employed because it is a 'statin'. As a drug class, statins have broad anti-inflammatory properties. Low-level inflammation is thought to be a potentially important mediator of the effects of psychosocial stress (including loneliness) on affect and vulnerability to depression. In this study we are using statins as an experimental tool to investigate this relationship further. Statins are widely prescribed agents that are regarded as very safe and so are suitable tools in this context. We have selected simvastatin because it is one of the most widely used statins and has an excellent safety profile, being also available 'over the counter'.
OTC	NCT04973800 ↗	Simvastatin and Emotional Processing (OxSTEP)	Recruiting	University of Oxford	N/A	2021-06-21	Simvastatin is being employed because it is a 'statin'. As a drug class, statins have broad anti-inflammatory properties. Low-level inflammation is thought to be a potentially important mediator of the effects of psychosocial stress (including loneliness) on affect and vulnerability to depression. In this study we are using statins as an experimental tool to investigate this relationship further. Statins are widely prescribed agents that are regarded as very safe and so are suitable tools in this context. We have selected simvastatin because it is one of the most widely used statins and has an excellent safety profile, being also available 'over the counter'.

All Clinical Trials for simvastatin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000553 ↗	HDL-Atherosclerosis Treatment Study (HATS)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1994-09-01	To measure the effects of lipid-lowering drugs and/or antioxidant vitamins on progression or regression of coronary heart disease as measured by quantitative angiography in patients with low high density lipoprotein (HDL) cholesterol.
NCT00000553 ↗	HDL-Atherosclerosis Treatment Study (HATS)	Completed	University of Washington	Phase 3	1994-09-01	To measure the effects of lipid-lowering drugs and/or antioxidant vitamins on progression or regression of coronary heart disease as measured by quantitative angiography in patients with low high density lipoprotein (HDL) cholesterol.
NCT00000620 ↗	Action to Control Cardiovascular Risk in Diabetes (ACCORD)	Completed	Centers for Disease Control and Prevention	Phase 3	1999-09-01	The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
NCT00000620 ↗	Action to Control Cardiovascular Risk in Diabetes (ACCORD)	Completed	National Eye Institute (NEI)	Phase 3	1999-09-01	The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
NCT00000620 ↗	Action to Control Cardiovascular Risk in Diabetes (ACCORD)	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 3	1999-09-01	The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
NCT00000620 ↗	Action to Control Cardiovascular Risk in Diabetes (ACCORD)	Completed	National Institute on Aging (NIA)	Phase 3	1999-09-01	The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.

Clinical Trial Conditions for simvastatin

Condition Name

Condition Name for simvastatin
Intervention	Trials
Hypercholesterolemia	91
Dyslipidemia	26
Atherosclerosis	23
Healthy	21

Condition MeSH

Condition MeSH for simvastatin
Intervention	Trials
Hypercholesterolemia	105
Dyslipidemias	54
Coronary Artery Disease	36
Diabetes Mellitus	36

Clinical Trial Locations for simvastatin

Trials by Country

Trials by Country for simvastatin
Location	Trials
United States	693
Canada	70
United Kingdom	41
Spain	39
Korea, Republic of	30

Trials by US State

Trials by US State for simvastatin
Location	Trials
California	47
Texas	41
Florida	36
New York	34
Ohio	29

Clinical Trial Progress for simvastatin

Clinical Trial Phase

Clinical Trial Phase for simvastatin
Clinical Trial Phase	Trials
PHASE4	1
PHASE2	6
PHASE1	4

Clinical Trial Status

Clinical Trial Status for simvastatin
Clinical Trial Phase	Trials
Completed	376
Unknown status	63
Recruiting	51

Clinical Trial Sponsors for simvastatin

Sponsor Name

Sponsor Name for simvastatin
Sponsor	Trials
Merck Sharp & Dohme Corp.	93
AstraZeneca	17
National Heart, Lung, and Blood Institute (NHLBI)	14

Sponsor Type

Sponsor Type for simvastatin
Sponsor	Trials
Other	623
Industry	269
NIH	44

Simvastatin Clinical Trials Update, Market Analysis and Projections

Last updated: April 24, 2026

What is simvastatin and how is it positioned today?

Simvastatin is an HMG-CoA reductase inhibitor (statin) marketed as a generic long-established cardiovascular medicine for lowering LDL cholesterol and reducing risk of major cardiovascular events in appropriate patient populations. The drug’s market position is anchored by (1) mature clinical evidence, (2) off-patent status in most major markets, and (3) broad guideline inclusion as an oral, low-cost lipid-lowering backbone therapy.

Therapeutic scope (typical label use):

• Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia) and mixed dyslipidemia
• Prevention of cardiovascular events in patients at elevated risk
• Adjunct to diet and other lipid-lowering strategies

What do the latest clinical trials data indicate?

Trial landscape is dominated by non-invention studies

Simvastatin is rarely the lead investigational drug in late-stage innovation programs. Current clinical activity tends to fall into one or more categories:

• Generic bioequivalence and formulation studies (to support approvals and switch brands)
• Comparative effectiveness in real-world cohorts
• Repurposing or combination strategy studies, often with short follow-up or surrogate endpoints
• Safety-focused or adherence-focused studies (switching, persistence, tolerability)

Practical implication for investors and R&D planners: the clinical trial “update” for simvastatin is less about new mechanism-of-action breakthroughs and more about incremental evidence for use in specific subgroups, regimen optimization, and pharmacoeconomic outcomes tied to adherence and generic substitution.

Current evidence base remains guideline-driven

Large established evidence sets remain the principal clinical reference points (e.g., statin outcome trials across multiple statins; simvastatin-specific outcomes are well characterized in landmark programs). Recent trial publications are more frequently meta-analyses, registry studies, or secondary analyses rather than new pivotal efficacy trials.

Where this matters commercially: pipeline value is low because simvastatin is not a protected asset; trial activity tends to support generics and local label extensions rather than new exclusivity.

Is there any meaningful “new” clinical development that can shift the market?

The core clinical lever for simvastatin is access and use, not novel efficacy. Market-shifting developments are typically driven by:

• Guideline updates that change preferred statin intensity or sequencing
• Patent status at the country level (switching timing affects revenue pools, not biology)
• Formulation and payer policies that change utilization (step-therapy, generic mandates, formulary preference)
• Safety or drug-interaction updates that change prescribing behavior

Because simvastatin has been generic for years, the most investable “development” is payer and access strategy, not late-stage clinical innovation.

How big is the simvastatin market and what segments matter most?

Market size and supplier structure

Simvastatin is sold as:

• Tablet formulations in multiple strengths
• Generic products from many manufacturers across major markets
• Repackaged versions and fixed dosing regimens under different brand/generic portfolios

Market dynamics that dominate revenue:

• Price compression from generic competition
• Volume sensitivity to guideline penetration and adherence
• Formulary placement (hospital and outpatient)
• Switching from higher-cost statins under payer step therapy

Key demand segments

The most durable demand segments are:

• Patients requiring moderate- to high-intensity LDL reduction where simvastatin remains a guideline-supported option
• Hypercholesterolemia and mixed dyslipidemia treatment lines
• Long-term secondary prevention populations

What drives utilization in practice

• Generic availability and low acquisition cost
• Clinician familiarity and long safety record
• Payer protocols that steer patients toward inexpensive statins
• Adherence influenced by tolerability, dosing convenience, and copayment levels

What is the competitive landscape versus other statins?

Direct competitive set

Simvastatin competes within the statin class, particularly with:

• Atorvastatin
• Rosuvastatin
• Lower-priced generics within each category
• Fixed-dose combination lipid therapies in some markets (where used)

Competitive outcomes

• Price: simvastatin generally offers one of the lowest acquisition costs within common statin options, which supports payer preference.
• Prescribing patterns: atorvastatin and rosuvastatin sometimes gain share because of perceived potency, dosing convenience, and clinician preference for higher-intensity regimens.
• Safety considerations: simvastatin has known interaction and myopathy risk considerations, particularly at higher doses and with certain interacting agents; these can constrain use in some patient segments.

What market projections are realistic for simvastatin through the next 5 years?

Projection logic for an off-patent, low-cost generic

Without brand exclusivity, projections are primarily driven by:

• Growth in the treated population (ageing, cardiovascular risk prevalence)
• Stability or decline in real pricing due to ongoing generic competition
• Shifts in market share to competing statins and away from simvastatin in some guideline or payer contexts

Base-case projection (directional)

• Unit volumes: stable to modestly declining, depending on whether prescribers shift intensity preference toward other statins.
• Revenue value: likely flat to declining in nominal terms due to continued price erosion, offset partly by volume and tender-driven procurement.
• Share: likely modestly pressured over time by atorvastatin and rosuvastatin, but remains resilient due to low cost and entrenched formulary presence.

Upside and downside scenarios

• Upside: payer reinforcement of low-cost statin step therapy; increased adherence programs; inclusion of simvastatin in cost-effective regional formularies.
• Downside: stronger payer movement to other generics with better dosing profiles; tightening of dosing for interaction risk; guideline changes favoring other statins for certain intensities.

Actionable commercial read-through: expect simvastatin to behave like a mature commodity therapy: revenue is mostly determined by distribution and procurement economics, not by clinical differentiation.

What regulatory and safety factors can affect demand?

Interaction and dosing constraints

Simvastatin safety management is a major determinant of prescribing:

• Risk of myopathy/rhabdomyolysis increases with drug-drug interactions, higher doses, and specific patient risk factors
• Clinical practice emphasizes careful selection of dose and avoidance of contraindicated interacting medicines

These safety practices can reduce use in high-interaction polypharmacy cohorts, limiting penetration even when cost favors simvastatin.

Where does simvastatin still offer business value?

1) Generic manufacturing and supply

• Scale and cost competitiveness drive profitability
• Procurement contracts and supply reliability influence outcomes more than clinical novelty

2) Formulary strategy

• Payer placement is the main “marketing lever”
• Adherence programs can protect share, especially where substitution to other statins is common

3) Product differentiation that does not require new exclusivity

• Strength portfolios
• Bioequivalence and manufacturing capability
• Tablet stability, patient-friendly dosing packs, and low total cost per adherence cycle

Clinical trial update summary (what to treat as “signal”)

Because simvastatin is off patent, “trial updates” generally do not imply a new product lifecycle. The most meaningful signals are:

• Evidence that preserves low-cost utilization (real-world effectiveness, adherence outcomes)
• Data that refine safe dosing and interaction management for clinicians
• Regulatory changes and label updates that affect contraindications or dose limits
• Country-level substitution and procurement dynamics reflected through ongoing generic approvals

Market analysis summary and projection

Simvastatin is a mature, generic statin with stable clinical relevance and ongoing demand tied to affordability and cardiovascular prevention. Near-term market outcomes depend on pricing and formulary behavior, with share competition from other statins shaping volume distribution. Value growth is limited; profitability is more sensitive to manufacturing cost and tender economics than to clinical differentiation.

---

Key Takeaways

• Simvastatin is an off-patent, guideline-relevant statin; the clinical update is mostly bioequivalence, real-world, and safety management rather than new pivotal efficacy.
• Market revenue is primarily driven by unit volumes plus price erosion from generic competition, not by innovation.
• Competitive pressure from atorvastatin and rosuvastatin affects share, but simvastatin remains resilient due to low cost and entrenched formulary position.
• Over the next five years, expect stable-to-modestly changing volume and flat-to-declining nominal revenue unless payer policies strongly reinforce lowest-cost statin use.

---

FAQs

1) Does simvastatin still have a meaningful clinical pipeline?

Clinical activity exists, but it is typically incremental (bioequivalence, real-world studies, and safety or adherence research) rather than new mechanism-defining development.

2) What is the biggest market risk for simvastatin?

Ongoing generic price compression and share shift toward other statins, especially where prescribers or payers prefer higher potency or dosing convenience.

3) What is the biggest market tailwind for simvastatin?

Cost-focused formularies and step-therapy protocols that keep patients on low-acquisition-cost statin therapy.

4) Do safety considerations materially limit simvastatin use?

Yes. Myopathy risk and drug-drug interaction management influence prescribing, especially in polypharmacy and higher-dose contexts.

5) How should investors view simvastatin market projections?

As a mature commodity class asset where procurement economics and market access drive returns more than late-stage clinical differentiation.

---

References

[1] U.S. Food and Drug Administration. (n.d.). Simvastatin information and prescribing information. FDA. https://www.accessdata.fda.gov/ (accessed via relevant simvastatin labeling pages)
[2] National Library of Medicine. (n.d.). Simvastatin studies and clinical trial listings (ClinicalTrials.gov search results). ClinicalTrials.gov. https://clinicaltrials.gov/
[3] Cholesterol Treatment Trialists’ Collaboration. (2010). Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. The Lancet, 376, 1670-1681. https://doi.org/10.1016/S0140-6736(10)61328-5
[4] American College of Cardiology/American Heart Association. (2018). 2018 AHA/ACC guideline on the management of blood cholesterol. Circulation, 139(25), e1082-e1143. https://doi.org/10.1161/CIR.0000000000000625
[5] European Society of Cardiology/European Atherosclerosis Society. (2019). 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal, 41(1), 111-188. https://doi.org/10.1093/eurheartj/ehz669